Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of a lipophilic compound and a pharmaceutically acceptable carrier adapted for pen-ocular transdermal delivery of the lipophilic compound to one or more periorbital glands and/or the ocular surface tissues of a subject. Further provided herein are methods of using such pharmaceutical compositions for providing relief of one or more signs or symptoms of an ocular disease, methods of using one or more Meibomian glands (and meibum therein) as a drug delivery system for a lipophilic compound (e.g., a steroid) to the ocular surface, and kits related thereto.
1. A method of providing palliative or therapeutic relief of dry eye disease or blepharitis in a subject, comprising administering to the subject a pharmaceutical composition comprising:
a) a therapeutically effective amount of a steroid, wherein the steroid is a compound of Formula I, and wherein the compound of Formula I is of the structure:
and
b) a pharmaceutically acceptable carrier adapted for peri-ocular transdermal delivery of the steroid to one or more peri-orbital glands of a subject;
wherein the pharmaceutical composition comprises the steroid at a concentration between 0.01% and 1% weight per weight (w/w),
wherein the pharmaceutical composition is specifically formulated for peri-ocular delivery,
wherein the pharmaceutical composition is topically administered to the external portion of an upper and/or lower eyelid of the subject,
wherein the steroid is delivered to an ocular surface of the subject via the one or more peri-orbital glands of the subject, and
wherein the pharmaceutical composition is administered one time each day that it is administered.
2. The method of claim 1 , wherein the steroid is delivered to the ocular surface of the subject via the Meibomian gland.
3. The method of claim 1 , wherein the one or more peri-orbital glands are selected from the group consisting of a Meibomian gland, a lacrimal gland, an accessory lacrimal gland, and any combinations thereof.
4. The method of claim 1 , wherein the pharmaceutical composition comprises the steroid at a concentration between 0.01% and 0.5% weight per weight (w/w).
5. The method of claim 4 , wherein the pharmaceutical composition comprises the steroid at a concentration of about 0.2% w/w.
6. The method of claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of an ointment, cream, lotion, gel, emulsion, suspension, oil, foam, transdermal patch, spray, and any combinations thereof.
7. The method of claim 6 , wherein the cream comprises an oil-in-water base or a water-in-oil base.
8. The method of claim 6 , wherein the cream comprises white petrolatum, mineral oil, propylene glycol, ST-cyclomethicone-SNF, emulsifier 10, ST-elastomer-10, sodium phosphate dibasic anhydrous, citric acid, and purified water.
9. The method of claim 8 , wherein the cream comprises the steroid at a concentration of about 0.2% w/w, about 48% w/w white petrolatum, about 8% w/w mineral oil, about 8% w/w propylene glycol, about 6.6% w/w ST-cyclomethicone-SNF, about 3.3% w/w emulsifier 10, about 2% w/w ST-elastomer-10, about 0.06% w/w sodium phosphate dibasic anhydrous, about 0.05% w/w citric acid anhydrous, and purified water.
10. The method of claim 8 , wherein the cream further comprises benzalkonium chloride (BAK), or propylparaben and methylparaben.
11. The method of claim 1 , wherein the pharmaceutical composition is administered for one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, 10 weeks, 11 weeks, 12 weeks, 24 weeks, 36 weeks, or 48 weeks or more.
12. The method of claim 1 , wherein the subject is a human or a non-human animal.